ArcherDX announced that it has won breakthrough device designation from the FDA for its personalized cancer monitoring (PCM) technology. Boulder, Colo.-based ArcherDX’s PCM platform is designed for minimally invasive monitoring and recurrence surveillance for early-stage cancer treatment. It is meant to offer healthcare providers access to genomic information in their laboratory. ArcherDX also recently won […]
3Derm lands FDA breakthrough device designations for autonomous skin cancer AI
3Derm Systems announced that it won two FDA breakthrough device designations for its 3DermSpot autonomous artificial intelligence imaging system for detecting skin cancer. The 3DermSpot is an algorithm designed to use AI and highly standardized skin images to autonomously detect melanoma, squamous cell carcinoma and basal cell carcinoma. Autonomous AI has the potential to provide […]
OncoCyte announces $7.6m offering
Molecular diagnostics company OncoCyte (NYSE:OCX) announced that two investors have agreed to purchase nearly $8 million of its common stock in a registered offering. Pura Vida Investments and another institutional investor combined for the $7.6 million offering, which was completed directly with the investors and included no placement agent fees. OncoCyte is slated to sell […]
CDx Diagnostics raises $11m for tech to spot pre-cancerous cells in esophagus
CDx Diagnostics‘ parent company has raised more than $11 million in its latest money-raise as it continues to promote its WATS3D diagnostic platform for spotting pre-cancerous cells in the esophagus. Six investors provided money to CDx Medical Holdings, according to the SEC Form D dated Dec. 16. The company had sought up to $17.3 million. […]
Proton therapy lowers risk of side effects for cancer patients, study says
Findings from a new study claim that proton therapy leads to a significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared to traditional radiation. Although cure rates between the proton therapy and radiation groups remain almost identical, the study conducted at the Perelman School of Medicine […]
Delcath Systems announces reverse stock split
A reverse stock split went into effect today for Delcath Systems (OTC:DCTH) — developer of the Chemostat hepatic delivery system for treating cancer. The 1-for-700 reverse stock split is meant to reduce the number of common stock shares and shares reserved for issuance to 1.2 million, from a previous 1.4 billion. The authorized number of shares […]
CEL-SCI prices $5.5m common stock offering
Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it priced an underwritten public offering of common stock with expected gross proceeds of $5.5 million. Vienna, Va.–based Cel-Sci is offering 606, 395 shares of common stock at a price of $9.07 per share to total the $5.5 million before deducting underwriting discounts and other estimated […]
Could an algorithm improve breast cancer treatment?
A study from researchers at Penn Medicine revealed that MRI and an algorithm-based field of medicine called radiomics could help characterize the heterogeneity of cancer cells in a tumor and allow for better understanding of the causes and progression of individual diseases. The study, published in Clinical Cancer Research, examines radiomics, which uses algorithms to extract […]
OncoSec $30m fundraise threatened by spat
OncoSec Medical (NSDQ:ONCS) is embroiled in a lawsuit and proxy war over a $30 million money-raise as it seeks to continue development of its cancer treatment technology. The company — headquartered in San Diego and Pennington, N.J. — sent a letter to shareholders today in which it countered what it described as false and misleading statements […]
Varian Medical spending extra on Endocare and Alicon purchase
Radiation oncology treatments and software maker Varian Medical Systems (NYSE:VAR) announced today that it updated its previously reported GAAP preliminary financial results for the fourth quarter and fiscal 2019. Earlier this week, the company uncovered new information and determined that the financial performance of its recently acquired Endocare and Alicon business was better than previously understood […]
BD warns of international device shortages in EO plant legal filing
The Georgia environmental chief’s effort to shut down a Becton Dickinson (NYSE:BDX) medtech sterilization plant could cause widespread shortages of commonly used devices for which BD has a large market share, the company said today in a court filing. On Tuesday, Georgia state Environmental Protection Division director Richard Dunn filed a motion with Newton County Superior Court […]
- 1
- 2
- 3
- …
- 79
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube